Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Boris Shulgin, Yuri Kosinsky, Andrey Omelchenko, Lulu Chu, Ganesh Mugundu, Sergey Aksenov, Rodrigo Pimentel, Garrett DeYulia, Geoffrey Kim, Kirill Peskov & Gabriel Helmlinger. (2020) Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. OncoImmunology 9:1.
Read now
Read now
Barouyr Baroudjian, Dimitri Arangalage, Stefania Cuzzubbo, Baptiste Hervier, Celeste Lebbé, Gwenael Lorillon, Abdellatif Tazi, Gerard Zalcman, Mohamed Bouattour, Frédéric Lioté, Jean-François Gautier, Solenn Brosseau, Nelson Lourenco & Julie Delyon. (2019) Management of immune-related adverse events resulting from immune checkpoint blockade. Expert Review of Anticancer Therapy 19:3, pages 209-222.
Read now
Read now
Articles from other publishers (24)
R. N. Mustafin. (2023) Prospects of epigenetic therapy of head and neck squamous cell carcinoma. Head and Neck Tumors (HNT) 13:2, pages 26-34.
Crossref
Crossref
Rustam N. Mustafin. (2023) Options for the development of colorectal cancer immunotherapy. Kazan medical journal 104:4, pages 564-572.
Crossref
Crossref
R. N. Mustafin. (2023) The Method of Viral Mimicry in Oncology and Prospects for its Improvement. The Russian Archives of Internal Medicine 13:3, pages 165-174.
Crossref
Crossref
Xiangyi Kong, Li Chen, Zhaohui Su, Ryan J. Sullivan, Steven M. Blum, Zhihong Qi, Yulu Liu, Yujia Huo, Yi Fang, Lin Zhang, Jidong Gao & Jing Wang. (2023) Toxicities associated with immune checkpoint inhibitors: a systematic study. International Journal of Surgery 109:6, pages 1753-1768.
Crossref
Crossref
Yu Fujiwara, Nobuyuki Horita, Matthew Harrington, Ho Namkoong, Hirotaka Miyashita & Matthew D. Galsky. (2022) Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. Cancer Immunology, Immunotherapy 71:12, pages 2837-2848.
Crossref
Crossref
Cathrin L. C. Gudd & Lucia A. Possamai. (2022) The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. Cancers 14:8, pages 1913.
Crossref
Crossref
Yuya Hirasawa, Kiyoshi Yoshimura, Hiroto Matsui, Yutaro Kubota, Hiroo Ishida, Jun Arai, Masashi Sakaki, Nao Oguro, Midori Shida, Makoto Taniguchi, Kazuyuki Hamada, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Ryotaro Ohkuma, Takehiko Sambe, Atsushi Horiike, Chiyo K. Imamura, Eisuke Shiozawa, Satoshi Wada, Junji Tsurutani, Sanju Iwamoto, Naoki Uchida, Yuji Kiuchi, Genshu Tate, Shinichi KobayashiTakuya Tsunoda. (2021) A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Medicine 100:23, pages e25774.
Crossref
Crossref
Zhi Li, Wen-Qi Gao, Peng Wang, Tian-Qi Wang, Wen-Chao Xu, Xin-Yu Zhu & Hui Liu. (2020) Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-γ Signaling. Current Cancer Drug Targets 20:11, pages 868-874.
Crossref
Crossref
Shiori Hasegawa, Hiroaki Ikesue, Satoshi Nakao, Kazuyo Shimada, Ririka Mukai, Mizuki Tanaka, Kiyoka Matsumoto, Misaki Inoue, Riko Satake, Yu Yoshida, Fumiya Goto, Tohru Hashida & Mitsuhiro Nakamura. (2020) Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiology and Drug Safety 29:10, pages 1279-1294.
Crossref
Crossref
Yingying Yang, Joel R. Hecht, Sandy Ting Liu, Melissa J. Cohen, Steven D. Hart, Hanlin L. Wang & Anthony P. Heaney. (2020) Caution Advised Using Combination Ketoconazole and PD-1 Inhibitors. AACE Clinical Case Reports 6:5, pages e239-e242.
Crossref
Crossref
Christine Hsu, John L. Marshall & Aiwu Ruth He. (2020) Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment. The Oncologist 25:2, pages 105-111.
Crossref
Crossref
Luyao Wang, Qingxia Ma, Ruixue Yao & Jia Liu. (2020) Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. International Immunopharmacology 79, pages 106088.
Crossref
Crossref
Grace Wakabayashi, Yu-Ching Lee, Frank Luh, Chun-Nan Kuo, Wei-Chiao Chang & Yun Yen. (2019) Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. Journal of Biomedical Science 26:1.
Crossref
Crossref
Michael Friedlander, Tarek Meniawy, Ben Markman, Linda Mileshkin, Paul Harnett, Michael Millward, Joanne Lundy, Alison Freimund, Christie Norris, Song Mu, John Wu, Virginia Paton & Bo Gao. (2019) Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. The Lancet Oncology 20:9, pages 1306-1315.
Crossref
Crossref
Naoshi Nishida & Masatoshi Kudo. (2019) Liver damage related to immune checkpoint inhibitors. Hepatology International 13:3, pages 248-252.
Crossref
Crossref
Huan-huan Ji, Xue-wen Tang, Zhi Dong, Lin Song & Yun-tao Jia. (2019) Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS. Clinical Drug Investigation 39:3, pages 319-330.
Crossref
Crossref
Bo Yang, Tingjun Liu, Yang Qu, Hangbo Liu, Song Guo Zheng, Bin Cheng & Jianbo Sun. (2018) Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers. Frontiers in Oncology 8.
Crossref
Crossref
Marie-Léa Gauci, Barouyr Baroudjian, Charlotte Zeboulon, Cécile Pages, Nicolas Poté, Olivier Roux, Mohamed Bouattour & Céleste Lebbé. (2018) Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?. Journal of Hepatology 69:2, pages 548-550.
Crossref
Crossref
Tycel J. PhillipsAndres Forero-TorresTaimur SherCatherine S. DiefenbachPatrick JohnstonMoshe TalpazJennifer PuliniLi ZhouPeggy ScherleXuejun ChenPaul M. Barr. (2018) Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. Blood 132:3, pages 293-306.
Crossref
Crossref
Mauricio Burotto, Juan G. Gormaz, Suraj Samtani, Nicolas Valls, Ricardo Silva, Carlos Rojas, Sergio Portiño & Carlos de la Jara. (2018) Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. Seminars in Oncology 45:3, pages 164-169.
Crossref
Crossref
Eleonora De Martin, Jean-Marie Michot, Barbara Papouin, Stéphane Champiat, Christine Mateus, Olivier Lambotte, Bruno Roche, Teresa Maria Antonini, Audrey Coilly, Salim Laghouati, Caroline Robert, Aurélien Marabelle, Catherine Guettier & Didier Samuel. (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. Journal of Hepatology 68:6, pages 1181-1190.
Crossref
Crossref
Bernardo Leon Rapoport, Ronwyn van Eeden, Vincent Sibaud, Joel B. Epstein, Jean Klastersky, Matti Aapro & Devan Moodley. (2017) Supportive care for patients undergoing immunotherapy. Supportive Care in Cancer 25:10, pages 3017-3030.
Crossref
Crossref
Bernardo L. Rapoport & Ronwyn van Eeden. 2017. Immunotherapy - Myths, Reality, Ideas, Future. Immunotherapy - Myths, Reality, Ideas, Future.
David Reeves. 2017. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
465
482
.